Lyell Immunopharma Inc. (NASDAQ: LYEL) announced the initiation of a Phase 3 clinical trial comparing its rondecabtagene autoleucel treatment to ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE